The report of sustained low-efficiency dialysis (SLED) treatment in fifteen patients of severe snakebite.
To investigate the therapeutic efficacy of sustained low-efficiency dialysis (SLED) in severe snakebite patients. Fifteen patients of severe snakebite was treated with SLED from July 2005 to August 2009 were included in the study. Central venous access was established in all patients. SLED was administered using Dialog(+) dialyzer (B. Braun, Germany). SLED sessions were 6-12 h in duration at a blood flow rate of 200 ml/min and a dialysate flow rate of 300 ml/min. Heparin or low molecular weight heparin was used as anticoagulant. Biochemical indicators, APACHE II scores before and after SLED, and clinical outcomes were evaluated. The levels of serum creatinine, glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, creatine kinase isozyme MB, and creatine kinase were significantly lower than the level before SLED (P < 0.05); the level of cholinesterase was significantly higher after SLED (P < 0.01); the APACHE II score before SLED was 14.1 ± 3.8, but decreased significantly to 7.9 ± 1.4, 6.2 ± 1.1, and 4.2 ± 0.8 on days 1, 2, and 7 after SLED, respectively (P < 0.01). Three patients died on days 1, 3, and 4 after SLED, respectively. The remaining twelve patients were either cured or showed improvement at the time of discharge. The survival rate was 80 % where as mortality was 20 %. SLED may be an effective treatment option in severe snakebite patients. It can reduce mortality, thereby, resulting in increased survival rates.
Department of Nephrology, The First Hospital of JingZhou, Yangtze University, Hangkongstreet 8, Jingzhou, 434000, Hubei, China, 45423626@qq.com.
Junzhang
J
Cheng
Dan
D
Wang
Shouliang
S
Hu
Hong
H
Jiang
Hongzhu
H
Lu
Qingfeng
Q
Lei
Juncheng
J
Liu
Fanli
F
Yuan
Rong
R
Chen
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000925:Anticoagulants / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D002802:Cholinesterases / Q000097:blood; D052279:Creatine Kinase, MB Form / Q000097:blood; D003404:Creatinine / Q000097:blood; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods*; D012720:Severity of Illness Index; D012909:Snake Bites / Q000097:blood / Q000401:mortality / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D052279:Creatine Kinase, MB Form; D002802:Cholinesterases